MEDI 3726

Drug Profile

MEDI 3726

Alternative Names: MEDI3726

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator MedImmune
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 20 Dec 2016 MedImmune plans a phase I trial for Prostate cancer in USA, United Kingdom and Switzerland (NCT02991911)
  • 01 Dec 2016 Phase-I clinical trials in Prostate cancer (Second-line therapy or greater, Metastatic disease) in USA (unspecified route) (NCT02991911)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top